Squarepoint Ops LLC Acquires 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS

Squarepoint Ops LLC lifted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 1,679.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,567 shares of the company’s stock after buying an additional 268,572 shares during the quarter. Squarepoint Ops LLC’s holdings in Xeris Biopharma were worth $1,329,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of XERS. FORA Capital LLC bought a new stake in Xeris Biopharma during the first quarter worth about $60,000. Tower Research Capital LLC TRC increased its stake in shares of Xeris Biopharma by 913.1% during the second quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after purchasing an additional 15,678 shares in the last quarter. Modern Wealth Management LLC purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $83,000. Landscape Capital Management L.L.C. bought a new stake in shares of Xeris Biopharma in the 1st quarter worth approximately $86,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Xeris Biopharma in the 2nd quarter worth approximately $95,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Oppenheimer reiterated an “outperform” rating and set a $18.00 price objective on shares of Xeris Biopharma in a research note on Friday, November 7th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Zacks Research lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $7.34 on Friday. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.14 and a 1 year high of $10.08. The company has a market cap of $1.22 billion, a P/E ratio of -73.39 and a beta of 0.57. The stock’s fifty day moving average price is $7.88 and its 200-day moving average price is $6.88.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The business had revenue of $74.38 million during the quarter, compared to analyst estimates of $74.19 million. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.01, for a total transaction of $116,835.67. Following the completion of the sale, the insider directly owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. The trade was a 1.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Patrick Shannon, Jr. sold 23,242 shares of the stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $7.46, for a total value of $173,385.32. Following the transaction, the insider directly owned 2,643,153 shares in the company, valued at $19,717,921.38. The trade was a 0.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 206,976 shares of company stock valued at $1,497,495 over the last ninety days. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.